VA
TNGX icon

VR Adviser’s Tango Therapeutics TNGX Stock Holding History

VR Adviser’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-500,000
Closed -$5.56M – 33
2021
Q1 		$5.56M Hold
500,000
– – 0.6% 24
2020
Q4 		$5.72M Hold
500,000
– – 0.84% 20
2020
Q3 		$5.18M Buy
+500,000
New +$5.11M 1.01% 19

Other funds holding TNGX

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VR Adviser's TNGX Position: Q2 2021 in Review

VR Adviser sold out of Tango Therapeutics (TNGX) in Q2 2021, closing a stake of 500,000 shares — an estimated $5.56M sold.

VR Adviser first reported a position in TNGX in Q3 2020 and held it in 3 quarters. The position peaked at $5.72M in Q4 2020. 31 funds tracked by Wall St. Rank hold TNGX as of Q2 2021.

  • VR Adviser reported no remaining Tango Therapeutics position as of Q2 2021 after selling out during the quarter.
  • VR Adviser sold 500,000 Tango Therapeutics shares in Q2 2021, an estimated $5.56M.
  • VR Adviser first reported a position in Tango Therapeutics in Q3 2020 and held it in 3 quarters.
  • VR Adviser's Tango Therapeutics position peaked at $5.72M in Q4 2020.
  • 31 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2021.

Based on VR Adviser's 13F filing for Q2 2021, filed 13 Aug 2021.